

Figure S1. Study design




Figure S2. Patient selection

DMT, disease-modifying therapy; HCPCS, Healthcare Common Procedure Coding System; MS, multiple sclerosis; NDC, National Drug Code.




Table S1. Rates of switching and discontinuation per DMT

First DMT (No. of patients treated)	No. of patients switched	No. of patients discontinued
Glatiramer acetate (47)	8	7
Interferon beta-1a (30)	9	0
Dimethyl fumarate (7)	2	1
Natalizumab (5)	0	1
Interferon beta-1b (4)	0	0
Fingolimod (4)	0	0
Peginterferon beta-1a (1)	0	0

DMT: disease-modifying therapy.